Are Medical Stocks Lagging Arbutus Biopharma ( ABUS ) This Year?
Here is how Arbutus Biopharma (ABUS) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Down 10.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Boston Scientific ( BSX )
Boston Scientific (BSX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near ...
HOLX Stock Gains on FDA & CE Approval for Automated Molecular GI Tests
Hologic's shares rise after receiving FDA clearance and CE mark for its rapid molecular GI assays on the Panther Fusion platform.
The Zacks Analyst Blog Highlights Boston Scientific, Union Pacific, Realty Income and Weyco
BSX, UNP, O, and WEYS stand out with strong sector performance, resilient cash flows, and strategic growth moves, despite headwinds from tariffs, e-commerce, and macro uncertainties.
Boston Scientific ( BSX ) Stock Dips While Market Gains: Key Facts
The latest trading day saw Boston Scientific (BSX) settling at $95.85, representing a -1.82% change from its previous close.
Hologic Bets on Endomagnetics to Fuel Interventional Breast Momentum
HOLX's Interventional Breast business hits $100M as Endomag products boost recurring revenues and margins.
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million - Boston Scientific ( NYSE:BSX ) , Elutia ( NASDAQ:ELUT )
- Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market -
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million
- Strengthened balance sheet to fully fund development and launch of NXT-41 platform ...
Boston Scientific To Rally More Than 35%? Here Are 10 Top Analyst Forecasts For Wednesday - Boston Scientific ( NYSE:BSX ) , Banc of California ( NYSE:BANC )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Telsey Advisory Group raised Victoria's Secret & Co ( NYSE:VSCO ) price target from $24 to $29.
Unlocking Cures: How AI is Reshaping Cancer Research & Healthcare ETFs?
AI's growing role in cancer research, and a new federal push for pediatric oncology, are powering gains in key healthcare ETFs.
IDEXX Laboratories Stock Rallies 52.9% YTD: What's Behind the Drive?
IDXX soars 52.9% YTD, fueled by strong CAG Diagnostics growth, global expansion and rising demand for software solutions.
Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?
PODD stock rallies 37.4% in a year, fueled by Omnipod 5 adoption, global launches and expanding reach in diabetes care.
If You Invested $1000 In Boston Scientific Stock 15 Years Ago, You Would Have This Much Today - Boston Scientific ( NYSE:BSX )
Boston Scientific ( NYSE: BSX ) has outperformed the market over the past 15 years by 7.91% on an annualized basis producing an average annual return of 20.24%. Currently, Boston Scientific has a market capitalization of $145.17 billion.
Phibro Animal Health Stock Surges 82.1% YTD: What's Fueling It?
PAHC rallies 82% YTD with booming vaccines, MFAs and global expansion fueling investor confidence.
SoCalBio Investor & Partnership Conference to Feature Keynotes from SetPoint CEO Murthy Simhambhatla, PhD, and MedTech Industry Deal-Maker Ray Cohen
LOS ANGELES, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- The Southern California Biomedical Council ( SoCalBio ) today announced that two of Southern California's most accomplished life sciences executives -- Murthy Simhambhatla, PhD, President & CEO of SetPoint Medical, and Raymond W.
PAHC vs. BSX: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health ( PAHC Quick QuotePAHC - ) and Boston Scientific ( BSX Quick QuoteBSX - ) . But which of these two stocks offers value investors a better bang for their buck right now?
Is it a Prudent Move to Retain BSX Stock in Your Portfolio for Now?
Boston Scientific's acquisitions and WATCHMAN growth fuel optimism, but currency swings and macro pressures weigh on its outlook.
Which Stocks Win When Rates Fall? Goldman Picks These Surprising Names - Arista Networks ( NYSE:ANET ) , Axon Enterprise ( NASDAQ:AXON )
With Wall Street indices hitting fresh records and the Fed embracing a dovish pivot with further rate cuts on the table, Goldman Sachs wasted no time upgrading its S&P 500 target-but it's the bank's unusual stock picks that stand out.
Medtech Leader Erica Rogers Joins Ceribell Board of Directors - CeriBell ( NASDAQ:CBLL )
SUNNYVALE, Calif., Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- CeriBell, Inc. CBLL ( "Ceribell" or the "Company" ) , a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointment of Erica Rogers to its ...
Medtech Leader Erica Rogers Joins Ceribell Board of Directors
Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companies Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companies ...
Top 3 Health Care Stocks That May Explode In September - aTyr Pharma ( NASDAQ:ATYR ) , Boston Scientific ( NYSE:BSX )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
Neuromodulation Market is expected to generate a revenue of USD 9.32 Billion by 2032, Globally, at 9.27% CAGR: Verified Market Research®
Lewes, Delaware, Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- The Global Neuromodulation Market Size is projected to grow at a CAGR of 9.27% from 2026 to 2032, according to a new report published by Verified Market Research®.
Why Boston Scientific ( BSX ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Avanos Medical Buys Nexus Medical to Bolster Critical Care Portfolio
AVNS acquires Nexus Medical, adding its TKO connector to expand critical care offerings and drive immediate revenue and earnings growth.
Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
ENTX posts positive PK data for its first oral GLP-2 therapy, signaling a potential breakthrough in short bowel syndrome treatment.
CAH Strengthens Distribution With New Consumer Health Logistics Hub
Cardinal Health opens a 350,000-square-foot Consumer Health Logistics Center in Ohio, strengthening its pharmaceutical supply chain and advancing its multiyear infrastructure expansion strategy.
GEHC Expands Women's Health Portfolio With AI-Enabled Voluson
GE HealthCare debuts AI-powered Voluson Performance ultrasound systems, enhancing women's health imaging with faster, smarter diagnostics.
InspireMD Announces the Appointment of Dan Dearen to its Board of Directors
MIAMI, Sept. 17, 2025 ( GLOBE NEWSWIRE ) -- InspireMD, Inc. ( Nasdaq: NSPR ) ( "InspireMD" or the "Company" ) , developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors.
GEHC Eyes icometrix Buyout to Strengthen Neurology Imaging Portfolio
GE HealthCare moves to strengthen its neurology portfolio by acquiring icometrix, aiming to integrate AI-driven brain MRI solutions into its imaging platforms.
Is Boston Scientific ( BSX ) Outperforming Other Medical Stocks This Year?
Here is how Boston Scientific (BSX) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.
Boston Scientific ( BSX ) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Boston Scientific (BSX) settling at $105.23, representing a -2.65% change from its previous close.
Reasons to Retain Avanos Medical Stock in Your Portfolio Now
AVNS's solid Q2 performance, strong product demand, and strategic transformation support growth amid tariff and FX headwinds.
Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System
MBOT shares rise as FDA clears its LIBERTY robotic system, paving the way for U.S. market entry and fueling strong investor momentum.
Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million
- Transaction affirms the strength of Elutia's proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction ...
Cardinal Health Expands At-Home Solutions With New Texas Facility
CAH announces the opening of a new distribution center in Texas, which is likely to support its at-Home Solutions business.
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Boston Scientific ( NYSE:BSX )
Boston Scientific BSX has outperformed the market over the past 10 years by 7.72% on an annualized basis producing an average annual return of 20.31%. Currently, Boston Scientific has a market capitalization of $159.01 billion.
Disposable Endoscopes Market is expected to generate a revenue of USD 7.31 Billion by 2032, Globally, at 17.24% CAGR: Verified Market Research®
Lewes, Delaware, Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- The Global Disposable Endoscopes Market Size is projected to grow at a CAGR of 17.24% from 2026 to 2032, according to a new report published by Verified Market Research®.
MYGN Stock Might Gain on The Lancet Study Backing Precise MRD
Myriad Genetics' Precise MRD study in The Lancet shows ctDNA detection power in oligometastatic ccRCC, supporting oncology growth plans.
GEHC Stock Gains Following Launch of Revolution Vibe CT Imaging System
GE HealthCare's FDA-cleared Revolution Vibe CT promises faster, AI-driven cardiac imaging with improved clarity, boosting efficiency and patient comfort.
PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq
PacBio collaborates with EpiCypher to integrate Fiber-Seq and HiFi sequencing, advancing single-molecule epigenomics with new chromatin mapping tools.
Here's Why You Should Hold Cencora Stock in Your Portfolio Now
COR gains from strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose risks.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
ECL's strong Q2 results, innovation pipeline, and high-tech growth drivers support its long-term expansion despite macro headwinds.
HealthEquity Stock Gains as Q2 Earnings Beat Estimates, Revenues Up Y/Y
HQY's Q2 results reflect EPS growth of 25.6% year over year, revenue growth of 8.6% and a 12% increase in HSA. The company also updates its fiscal 2026 guidance.
Is Boston Scientific ( BSX ) a Buy as Wall Street Analysts Look Optimistic?
The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
STXS Launches First U.S. Robotic HD Mapping With MAGiC Sweep
Stereotaxis debuts MAGiC Sweep, the first U.S. robotic HD mapping catheter, marking a breakthrough in cardiac arrhythmia diagnosis and treatment.
Boston Scientific ( BSX ) Increases Despite Market Slip: Here's What You Need to Know
In the latest trading session, Boston Scientific (BSX) closed at $106.66, marking a +1.1% move from the previous day.
IRTC Unveils Positive AMALFI Trial Data Showing Higher AF Detection
iRhythm's AMALFI trial shows its Zio monitoring service boosts AF detection and speeds diagnosis, strengthening its edge in cardiac care.
GEHC Launches AI-Powered Vivid Pioneer Cardiac Ultrasound System
GE HealthCare's Vivid Pioneer, cleared by CE Mark and FDA, brings AI-powered speed, precision and efficiency to cardiac imaging.
How Do Investors Really Feel About Boston Scientific? - Boston Scientific ( NYSE:BSX )
Boston Scientific's BSX short percent of float has risen 14.55% since its last report. The company recently reported that it has 18.60 million shares sold short, which is 1.26% of all regular shares that are available for trading.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
